/

Società

Cr

Non verificato

Crinetics Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaMedicina Salute Benessere

2 comunicati stampa

Guarda tutti i comunicati

03/12/2025

Biotecnologia

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Fonte

Crinetics Pharmaceuticals, Inc.

Emittente

1.00

0

25/09/2025

Biotecnologia

Medicina Salute Benessere

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Fonte

Crinetics Pharmaceuticals, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0